• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of gutGutVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
Gut. Apr 2000; 46(4): 515–521.
PMCID: PMC1727902

Surface hydrophobicity of the rat colonic mucosa is a defensive barrier against macromolecules and toxins

Abstract

BACKGROUND—Mucosal surface hydrophobicity is a key factor of the gastric acid defence barrier. In the colon, surface hydrophobicity is high but its biological function remains unexplored.
AIMS—To investigate the functional changes of the barrier due to removal of the surface active phospholipid layer by a detergent, or to reinforcement of the surface active phospholipid by local application of a suspension of lipids.
METHODS—Surface hydrophobicity (contact angle measurement), colonic permeability (lumen to blood clearance of mannitol and dextran), and mucosal resistance against luminal aggression (distal colitis induced by dextran sodium sulphate, DSS) were investigated in three study groups: (a) rats pretreated with a detergent (Brij 35) known to remove surfactant lipids; (b) rats pretreated with a suspension of surface active lipids (tripalmitin and dipalmitoyl-phosphatidylcholine); and (c) control rats pretreated with the corresponding vehicles.
RESULTS—In controls, surface hydrophobicity was low on the caecal mucosa and high in colon and rectum. Detergent treatment reduced surface hydrophobicity, and increased colonic permeability to mannitol and dextran. Conversely, treatment with lipids increased surface hydrophobicity, and reduced colonic permeability. Administration of DSS induced a progressive loss of colonic surface hydrophobicity, and an increase in permeability to mannitol and dextran. Detergent treatment increased susceptibility to epithelial damage and mucosal inflammation by DSS. Treatment with lipids reduced susceptibility to DSS colitis.
CONCLUSION—Colonic surface hydrophobicity modulates permeability to hydrophilic molecules and protects against toxins.


Keywords: mucosal surface hydrophobicity; mannitol; dextran

Full Text

The Full Text of this article is available as a PDF (134K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Hills BA, Butler BD, Lichtenberger LM. Gastric mucosal barrier: hydrophobic lining to the lumen of the stomach. Am J Physiol. 1983 May;244(5):G561–G568. [PubMed]
  • Lichtenberger LM. The hydrophobic barrier properties of gastrointestinal mucus. Annu Rev Physiol. 1995;57:565–583. [PubMed]
  • Lugea A, Mourelle M, Guarner F, Domingo A, Salas A, Malagelada JR. Phosphatidylcholines as mediators of adaptive cytoprotection of the rat duodenum. Gastroenterology. 1994 Sep;107(3):720–727. [PubMed]
  • Butler BD, Lichtenberger LM, Hills BA. Distribution of surfactants in the canine gastrointestinal tract and their ability to lubricate. Am J Physiol. 1983 Jun;244(6):G645–G651. [PubMed]
  • Goddard PJ, Kao YC, Lichtenberger LM. Luminal surface hydrophobicity of canine gastric mucosa is dependent on a surface mucous gel. Gastroenterology. 1990 Feb;98(2):361–370. [PubMed]
  • Kao YC, Goddard PJ, Lichtenberger LM. Morphological effects of aspirin and prostaglandin on the canine gastric mucosal surface. Analysis with a phospholipid-selective cytochemical stain. Gastroenterology. 1990 Mar;98(3):592–606. [PubMed]
  • Hills BA, Kirwood CA. Gastric mucosal barrier: barrier to hydrogen ions imparted by gastric surfactant in vitro. Gut. 1992 Aug;33(8):1039–1041. [PMC free article] [PubMed]
  • Mack DR, Neumann AW, Policova Z, Sherman PM. Surface hydrophobicity of the intestinal tract. Am J Physiol. 1992 Jan;262(1 Pt 1):G171–G177. [PubMed]
  • Spychal RT, Marrero JM, Saverymuttu SH, Northfield TC. Measurement of the surface hydrophobicity of human gastrointestinal mucosa. Gastroenterology. 1989 Jul;97(1):104–111. [PubMed]
  • Tatsumi Y, Lichtenberger LM. Molecular association of trinitrobenzenesulfonic acid and surface phospholipids in the development of colitis in rats. Gastroenterology. 1996 Mar;110(3):780–789. [PubMed]
  • Lichtenberger LM, Romero JJ, Kao YC, Dial EJ. Gastric protective activity of mixtures of saturated polar and neutral lipids in rats. Gastroenterology. 1990 Aug;99(2):311–326. [PubMed]
  • Lugea A, Antolín M, Mourelle M, Guarner F, Malagelada JR. Deranged hydrophobic barrier of the rat gastroduodenal mucosa after parenteral nonsteroidal anti-inflammatory drugs. Gastroenterology. 1997 Jun;112(6):1931–1939. [PubMed]
  • Goddard PJ, Hills BA, Lichtenberger LM. Does aspirin damage canine gastric mucosa by reducing its surface hydrophobicity? Am J Physiol. 1987 Mar;252(3 Pt 1):G421–G430. [PubMed]
  • Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology. 1990 Mar;98(3):694–702. [PubMed]
  • Ni J, Chen SF, Hollander D. Effects of dextran sulphate sodium on intestinal epithelial cells and intestinal lymphocytes. Gut. 1996 Aug;39(2):234–241. [PMC free article] [PubMed]
  • Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest. 1993 Aug;69(2):238–249. [PubMed]
  • Eliakim R, Goetz GS, Rubio S, Chailley-Heu B, Shao JS, Ducroc R, Alpers DH. Isolation and characterization of surfactant-like particles in rat and human colon. Am J Physiol. 1997 Mar;272(3 Pt 1):G425–G434. [PubMed]
  • Dieleman LA, Ridwan BU, Tennyson GS, Beagley KW, Bucy RP, Elson CO. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology. 1994 Dec;107(6):1643–1652. [PubMed]
  • Dieleman LA, Palmen MJ, Akol H, Bloemena E, Peña AS, Meuwissen SG, Van Rees EP. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol. 1998 Dec;114(3):385–391. [PMC free article] [PubMed]
  • Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology. 1989 Mar;96(3):795–803. [PubMed]
  • Hollander D, Vadheim CM, Brettholz E, Petersen GM, Delahunty T, Rotter JI. Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor. Ann Intern Med. 1986 Dec;105(6):883–885. [PubMed]
  • Casellas F, Aguadé S, Soriano B, Accarino A, Molero J, Guarner L. Intestinal permeability to 99mTc-diethylenetriaminopentaacetic acid in inflammatory bowel disease. Am J Gastroenterol. 1986 Sep;81(9):767–770. [PubMed]
  • Jenkins RT, Jones DB, Goodacre RL, Collins SM, Coates G, Hunt RH, Bienenstock J. Reversibility of increased intestinal permeability to 51Cr-EDTA in patients with gastrointestinal inflammatory diseases. Am J Gastroenterol. 1987 Nov;82(11):1159–1164. [PubMed]
  • Teahon K, Smethurst P, Levi AJ, Menzies IS, Bjarnason I. Intestinal permeability in patients with Crohn's disease and their first degree relatives. Gut. 1992 Mar;33(3):320–323. [PMC free article] [PubMed]
  • Gardiner KR, Anderson NH, Rowlands BJ, Barbul A. Colitis and colonic mucosal barrier dysfunction. Gut. 1995 Oct;37(4):530–535. [PMC free article] [PubMed]
  • Stein J, Ries J, Barrett KE. Disruption of intestinal barrier function associated with experimental colitis: possible role of mast cells. Am J Physiol. 1998 Jan;274(1 Pt 1):G203–G209. [PubMed]
  • Jung HC, Eckmann L, Yang SK, Panja A, Fierer J, Morzycka-Wroblewska E, Kagnoff MF. A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion. J Clin Invest. 1995 Jan;95(1):55–65. [PMC free article] [PubMed]
  • Zareie M, McKay DM, Kovarik GG, Perdue MH. Monocyte/macrophages evoke epithelial dysfunction: indirect role of tumor necrosis factor-alpha. Am J Physiol. 1998 Oct;275(4 Pt 1):C932–C939. [PubMed]
  • Scheiman JM, Kraus ER, Bonnville LA, Weinhold PA, Boland CR. Synthesis and prostaglandin E2-induced secretion of surfactant phospholipid by isolated gastric mucous cells. Gastroenterology. 1991 May;100(5 Pt 1):1232–1240. [PubMed]
  • Tessner TG, Cohn SM, Schloemann S, Stenson WF. Prostaglandins prevent decreased epithelial cell proliferation associated with dextran sodium sulfate injury in mice. Gastroenterology. 1998 Oct;115(4):874–882. [PubMed]
  • Procaccino F, Reinshagen M, Hoffmann P, Zeeh JM, Lakshmanan J, McRoberts JA, Patel A, French S, Eysselein VE. Protective effect of epidermal growth factor in an experimental model of colitis in rats. Gastroenterology. 1994 Jul;107(1):12–17. [PubMed]
  • Egger B, Procaccino F, Lakshmanan J, Reinshagen M, Hoffmann P, Patel A, Reuben W, Gnanakkan S, Liu L, Barajas L, et al. Mice lacking transforming growth factor alpha have an increased susceptibility to dextran sulfate-induced colitis. Gastroenterology. 1997 Sep;113(3):825–832. [PubMed]
  • Egger B, Carey HV, Procaccino F, Chai NN, Sandgren EP, Lakshmanan J, Buslon VS, French SW, Büchler MW, Eysselein VE. Reduced susceptibility of mice overexpressing transforming growth factor alpha to dextran sodium sulphate induced colitis. Gut. 1998 Jul;43(1):64–70. [PMC free article] [PubMed]

Figures and Tables

Figure 1
Surface hydrophobicity of the colonic mucosa in control rats and in rats treated with 2% Brij 35 in the drinking water for two days. Data are presented as the mean (SEM) of five rats per group. *p<0.05 compared with control.
Figure 2
Surface hydrophobicity of the colonic mucosa in control rats and in rats treated with 2 ml of tripalmitin-phosphatidylcholine. Data are presented as the mean (SEM) of seven rats per group. *p<0.05 compared with control.
Figure 3
Surface hydrophobicity of the colonic mucosa in control rats, in rats treated with 1 ml 5% Brij 35 instilled into the colonic lumen, and in rats treated with 5% Brij 35 as above and 2 ml of a lipid suspension (tripalmitin-phosphatidylcholine) ...
Figure 4
Lumen to blood clearance of mannitol or dextran expressed as percentage of the dose administered intracolonically at time 0 to control rats and to rats treated with 2% Brij 35 in the drinking water for two days. Values are means (SEM) ...
Figure 5
Lumen to blood clearance of mannitol or dextran expressed as percentage of the dose administered intracolonically at time 0 to control rats and to rats treated with 2 ml of a lipid suspension (tripalmitin-phosphatidylcholine) instilled ...
Figure 6
Surface hydrophobicity of the colonic mucosa in control rats (day 0) and in rats treated with 4% dextran sodium sulphate (DSS) in the drinking water on days 1, 3, and 5 after exposure to DSS. Values are means (SEM) for five rats ...
Figure 7
Lumen to blood clearance of mannitol or dextran five hours after intracolonic administration of labelled probes in controls, and in rats treated with 4% dextran sodium sulphate (DSS) in the drinking water on days 1, 3, and 5 after ...
Figure 8
Colonic damage scores after administration of 4% DSS for five days in control rats, in rats pretreated with 2% Brij 35 for two days, and in rats treated with 2 ml enemas of a lipid suspension for three days before DSS and during the five ...

Articles from Gut are provided here courtesy of BMJ Group

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Compound
    Compound
    PubChem Compound links
  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...